EnKay Omics, Inc.

Evanston, IL · Biotech · Private

FungalMGx platform for discovering novel fungal natural products through metabologenomics—integrating genomics, bioinformatics, and metabolomics to predict biosynthetic gene clusters and correlate the

Grants
$512K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Organizing Fungal Strains into a Library of Natural Products and Their Biosynthetic Gene Clusters$256,061
Federal grantDepartment of Health and Human Services · Phase I · Organizing Fungal Strains into a Library of Natural Products and Their Biosynthetic Gene Clusters$256,061
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2255HNB Therapeutics LLC——
2256LightSeed, Inc.——
2257Biomed Protect, LLC—$2.0M
2258EnKay Omics, Inc.——
2259KARAMEDICA, INC.——
2260Origin Speech Therapy Inc.—$2.6M
2261TRAMPOLINE PHARMA, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.